SBIR/STTR Research Award
DIAGNOSTICS FOR IVERMECTIN RESISTANCE IN NEMATODES
Award amount
$49,957Program and phase
SBIR · Phase IAward year
1992Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Nemapharm, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
RECENTLY, RESISTANCE TO ANTHELMINTICS HAS EMERGED AS THE MOST IMPORTANT PROBLEM CONFRONTING THECONTROL OF PARASITIC NEMATODES OF RUMINANTS. RESISTANCE IN PARASITES OF OTHER ECONOMICALLY SIGNIFICANT ANIMALS HAS ALSO BEEN REPORTED AND THERE CAN BE LITTLE DOUBT THAT THE INCIDENCE OF RESISTANCE WILL INCREASE AND WILL ALSO EVENTUALLY APPEAR IN MEDICALLY IMPORTANT PARASITES OF MAN. THE IMPACT OF RESISTANCE HAS BEEN CONTAINED BY THE INTRODUCTION OF IVERMECTIN, THE MOST POTENT, AND ARGUABLY THE MOST EFFICACIOUS, ANTHELMINTIC EVER DEVELOPED. HOWEVER, RECENT REPORTS SUGGEST THAT DEVELOPMENT OF RESISTANCE MAY SOON REDUCE ITS VALUE. EXTENSIVE INVESTIGATIONS OF IVERMECTIN RESISTANCE IN THE MODEL NEMATODE CAENORHABDITIS ELEGANS HAVE GENERATED A SPECIFIC HYPOTHESIS REGARDING THE LIKELY FORM OF IVERMECTIN RESISTANCE IN PARASITICNEMATODES. THE GOALS OF PHASE I ARE TO TEST THE HYPOTHESIS AND TO IDENTIFY THE GENES RESPONSIBLE FOR IVERMECTIN RESISTANCE IN PARASITIC NEMATODES. DURING PHASE II THESE GENES WILLBE CLONED AND DIAGNOSTIC REAGENTS CAPABLE OF DETECTING IVERMENTIN RESISTANCE IN PARASITES WILL BE DEVELOPED. DIAGNOSTIC REAGENTS WILL PROVIDE EARLY WARNING OF EMERGING RESISTANCE AND AN ABILITY TO MONITOR THE EFFICACY OF NEW METHODS DESIGNED TO LIMIT, AND PREFERABLY REVERSE, THE GROWTH OF IVERMECTIN RESISTANT POPULATIONS.
Technology keywords
Not reported